A new COVID vaccine is due next month, but health experts and analysts say it is likely to be coolly received even as hospitalizations from "Eris", a variant of the Omicron form of the coronavirus, rise around the country.
NEW YORK, Aug 14 (Reuters) - A new COVID vaccine is due out next month, but health experts and analysts say it is likely to be coolly received even as hospitalizations from “Eris”, a variant of the Omicron form of the coronavirus, rise around the country.
Healthcare providers and pharmacies such as CVS Health (CVS.N) will start next month to offer the shot, updated to fight the Omicron version of the virus that has been dominant since last year.
They will be fighting declining concern about the virus, as well as fatigue and skepticism about the merits of this vaccine, Kaiser Family Foundation Director of Survey Methodology Ashley Kirzinger said.
As with the flu, Pfizer (PFE.N)/BioNTech SE (22UAy.DE), Moderna (MRNA.O) and Novavax (NVAX.O), have created versions of the COVID vaccine to try to match the variant they believe will be circulating this fall.
Dr. William Schaffner, an infectious diseases specialist at Vanderbilt University and a liaison to the CDC’s Advisory Committee on Immunization practices, said it is possible that the ACIP could make a weaker recommendation for younger, healthier people.
Dr. David Boulware, an infectious diseases specialist at the University of Minnesota, said that according to research he has published, people who are boosted have less severe symptoms for a shorter duration.
This is the best summary I could come up with:
NEW YORK, Aug 14 (Reuters) - A new COVID vaccine is due out next month, but health experts and analysts say it is likely to be coolly received even as hospitalizations from “Eris”, a variant of the Omicron form of the coronavirus, rise around the country.
Healthcare providers and pharmacies such as CVS Health (CVS.N) will start next month to offer the shot, updated to fight the Omicron version of the virus that has been dominant since last year.
They will be fighting declining concern about the virus, as well as fatigue and skepticism about the merits of this vaccine, Kaiser Family Foundation Director of Survey Methodology Ashley Kirzinger said.
As with the flu, Pfizer (PFE.N)/BioNTech SE (22UAy.DE), Moderna (MRNA.O) and Novavax (NVAX.O), have created versions of the COVID vaccine to try to match the variant they believe will be circulating this fall.
Dr. William Schaffner, an infectious diseases specialist at Vanderbilt University and a liaison to the CDC’s Advisory Committee on Immunization practices, said it is possible that the ACIP could make a weaker recommendation for younger, healthier people.
Dr. David Boulware, an infectious diseases specialist at the University of Minnesota, said that according to research he has published, people who are boosted have less severe symptoms for a shorter duration.
I’m a bot and I’m open source!